Skip to content

US · SKYE · BIOTECHNOLOGY

Skye Bioscience, Inc. (SKYE) intrinsic value and stock valuation

$0.70as of 2026-11-21 · Mkt cap 18.25M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Skye Bioscience, Inc. DCF and intrinsic value

InvestorsCraft values SKYE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SKYE’s statements →

Skye Bioscience, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92130 skyebioscience.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-55.92M
20122025
Free cash flow
-$-43.07M
20122025
Total equity
$20M+113.6% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-58.16M-$-30.19M-$-34.74M-$-18.31M-$-7.85M
Net income-$-55.92M-$-26.57M-$-37.64M-$-19.48M-$-8.52M
EPSd-$-1.41M-$-728.14K-$-5.37M-$-8.77M-$-5.23M
Operating cash flow-$-43.06M-$-25.24M-$-13.95M-$-12.74M-$-6.47M
Capital expenditure-$-10K-$-1.6M-$-10K-$-30K-$-90K
Free cash flow-$-43.07M-$-26.84M-$-13.96M-$-12.77M-$-6.57M
Total assets$28.3M$72.8M$11.9M$9.11M$9.86M
Total debt$270K$460K$4.62M$1.98M$2.14M
Net debt-$-5.61M-$-67.96M$3.36M$740K-$-6.85M
Total equity$20M$68.2M-$-2.13M-$-3.01M$5.86M
Cash and short-term investments$25.7M$68.4M$1.26M$1.24M$8.98M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$720K$0.00$0.00$0.00$0.00
Gross profit-$-720K$0.00$0.00$0.00$0.00
Research and development expenses$42.4M$18.7M$5.82M$6.01M$2.93M
Selling, general and administrative expenses$15.8M$17.7M$7.85M$6.09M$4.92M
Other expenses-$-720K-$-6.23M$21.1M$6.21M$0.00
Operating expenses$57.4M$30.2M$34.7M$18.3M$7.85M
Cost and expenses$58.2M$30.2M$34.7M$18.3M$7.85M
Interest income$1.88M$3.26M$100K$20K$0.00
Interest expense$0.00$970K$910K$660K$770K
Depreciation and amortization$720K$300K$120K$110K$30K
Ebitda-$-55.2M-$-25.29M-$-36.62M-$-18.7M-$-7.72M
Operating income-$-58.16M-$-30.19M-$-34.74M-$-18.31M-$-7.85M
Total other income/expenses, net$2.24M$3.64M-$-2.91M-$-1.16M-$-670K
Income before tax-$-55.92M-$-26.56M-$-37.64M-$-19.47M-$-8.52M
Income tax expense$10K$10K$0.00$10K$0.00
Net income-$-55.92M-$-26.57M-$-37.64M-$-19.48M-$-8.52M
Weighted average shares outstanding$39.7M$36.5M$7.01M$2.22M$1.63M
Weighted average diluted shares outstanding$39.7M$36.5M$7.01M$2.22M$1.63M
Balance sheet
20252024202320222021
Cash and short-term investments$25.7M$68.4M$1.26M$1.24M$8.98M
Net receivables$10K$10K$160K$70K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$27.1M$70.8M$11.7M$8.94M$9.61M
Property, plant and equipment, net$1.17M$1.88M$280K$160K$230K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.22M$1.94M$290K$170K$240K
Total assets$28.3M$72.8M$11.9M$9.11M$9.86M
Accounts payable$2.03M$570K$960K$1.79M$900K
Short-term debt$190K$180K$4.44M$1.98M$2.06M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.21M$4.34M$13.9M$12.1M$3.91M
Long-term debt$80K$270K$170K$0.00$80K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$80K$270K$170K$0.00$80K
Capital lease obligations$190K$460K$240K$80K$160K
Total liabilities$8.29M$4.61M$14.1M$12.1M$3.99M
Common stock$30K$30K$10K$0.00$480K
Retained earnings-$-186.87M-$-130.95M-$-104.38M-$-66.74M-$-47.26M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$20M$68.2M-$-2.13M-$-3.01M$5.86M
Total investments$19.9M$0.00$0.00$0.00$0.00
Total debt$270K$460K$4.62M$1.98M$2.14M
Net debt-$-5.61M-$-67.96M$3.36M$740K-$-6.85M
Cash flow statement
20252024202320222021
Net income-$-55.92M-$-26.57M-$-37.64M-$-19.48M-$-8.52M
Depreciation and amortization$720K$300K$120K$110K$30K
Stock-based compensation$7.77M$8.32M$990K$630K$870K
Change in working capital$4.73M-$-2.63M-$-470K-$-760K$650K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.4M-$-590K-$-700K$800K$520K
Net cash provided by operating activities-$-43.06M-$-25.24M-$-13.95M-$-12.74M-$-6.47M
Investments in property, plant and equipment-$-10K-$-1.6M-$-10K-$-30K-$-90K
Acquisitions, net$0.00$0.00$0.00$5.31M$0.00
Net cash used for investing activities-$-19.5M-$-250K$6.6M$5.21M-$-90K
Common stock issued$30K$83.6M$11.7M$0.00$6.06M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30K$83.6M$16.4M-$-210K$13.1M
Net change in cash-$-62.53M$58.1M$9.09M-$-7.74M$6.51M
Cash at end of period$5.88M$68.4M$10.3M$1.25M$8.99M
Operating cash flow-$-43.06M-$-25.24M-$-13.95M-$-12.74M-$-6.47M
Capital expenditure-$-10K-$-1.6M-$-10K-$-30K-$-90K
Free cash flow-$-43.07M-$-26.84M-$-13.96M-$-12.77M-$-6.57M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Skye Bioscience, Inc.

        Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

        CEO
        Punit Dhillon
        Employees
        12
        Beta
        2.94

        Explore

        Frequently asked questions

        What is the intrinsic value of Skye Bioscience, Inc. (SKYE)?

        InvestorsCraft does not currently publish an intrinsic value for SKYE. How the IC value is calculated.

        Is SKYE undervalued?

        InvestorsCraft does not publish an undervaluation signal for SKYE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.